QURE — Recent News Coverage
All news mentioning QURE in ESEN's AI-graded feed
News stories with QURE as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on QURE. See /coverage/QURE for the 30-day aggregate.
MANILATIMES.NET
·
2026-06-19
NEUTRAL
BULLISH
CORR0.25
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
$QURE
◈ ESEN AI
uniQure (QURE) reported preliminary Phase I/IIa data for AMT-260, a gene therapy candidate targeting refractory mesial temporal lobe epilepsy. The early-stage readout demonstrates tolerability with no serious adverse ev…
SEEKINGALPHA.COM
·
2026-06-18
NEUTRAL
BULLISH
CORR0.35
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE)
$QURE
◈ ESEN AI
UniQure (QURE) has received a regulatory tailwind with the FDA's decision to reopen the Biologics License Application (BLA) pathway for AMT-130, its investigational gene therapy targeting Huntington's disease. This regu…
SEEKINGALPHA.COM
·
2026-06-17
HIGH
BULLISH
CORR0.42
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)
$QURE
◈ ESEN AI
uniQure (QURE) received a significant regulatory milestone when the FDA accepted Phase 1/2 data for AMT-130 under accelerated approval pathway for Huntington's disease treatment. This represents a critical de-risking ev…
CNBC
·
2026-06-17
NEUTRAL
NEUTRAL
CORR0.15
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
$QURE
◈ ESEN AI
QURE is moving forward with FDA approval pursuit for its Huntington's disease gene therapy despite prior regulatory friction. This represents a pivotal moment for the biotech firm, as it navigates a contentious relation…
MANILATIMES.NET
·
2026-06-17
NEUTRAL
BULLISH
CORR0.35
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
$QURE
◈ ESEN AI
uniQure (QURE) announced a path toward Biologics License Application (BLA) submission for AMT-130, its gene therapy candidate for Huntington's disease. The 3-year Phase I/II analysis is being positioned as sufficient pr…
EXPLORE OTHER FILTERS